European Equities Traded in the US as American Depositary Receipts Tumble in Friday Trading; Down 4.6% for Week

MT Newswires Live12-21 00:12

European equities traded in the US as American depositary receipts were dropping sharply late Friday morning, falling 1.89% to 1,275.63 on the S&P Europe Select ADR Index, which is down 4.6% for the week.

From continental Europe, the gainers were led by furniture maker Natuzzi (NTZ) and telecommunications company VEON (VEON), which advanced 8.4% and 3.4%, respectively. They were followed by medical device maker EDAP TMS (EDAP) and biotech firm BioNTech (BNTX), which increased 1.9% and 1.3%, respectively.

The decliners from continental Europe were led by pharmaceutical company Novo Nordisk (NVO) and accommodations booking company trivago (TRVG), which fell 20% and 5.3%, respectively. They were followed by biopharmaceutical company Cellectis (CLLS) and 3D printer company Materialise (MTLS), which were down 2.1% and 1.7%, respectively.

From the UK and Ireland, the gainers were led by biotech firm Autolus Therapeutics (AUTL) and cruise line operator Carnival (CUK), which rose 3.8% and 3.3%, respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and pharmaceutical company Silence Therapeutics (SLN), which were up 2.7% and 2.6%, respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company Mereo BioPharma Group (MREO) and software firm Endava (DAVA), which were down 2.4% and 1.6%, respectively. They were followed by biotech firm Trinity Biotech (TRIB) and alcoholic beverage company Diageo (DEO), down 1.2% and 1%, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment